• Recruiting

NCT04174196: Phase 2: A Study of Lenalidomide and CC-486 With Radiation Therapy in Plasmacytoma

LENAZART Study

LEN-AZA-RT

NCT04174196: Phase 2: A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma

lenazart

NCT04174196: Phase 2: A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma


The purpose of this study is to investigate if the combination of CC-486 with lenalidomide and radiation therapy is a safe and effective treatment for plasmacytoma.


Sponsor

Memorial Sloan Kettering Cancer Center

 

ClinicalTrials.gov Identifier: NCT04174196

Official Title: A Pilot Study Evaluating Lenalidomide and CC-486 in Combination With Radiotherapy For Patients With Plasmacytoma (LENAZART Study)

First Posted : November 22, 2019

Click here for details on ClinicalTrials.gov

 

Drug: CC-486

Drug: Lenalidomide

Radiation: Radiation Therapy

 

Lenalidomide: National Cancer Institute

Lenalidomide: MedlinePlus Drug Information


CC-486

oral hypomethylating agent, CC-486 (azacitidine tablets, Onureg)

Azacitidine (Code C288)

4-Amino-1-beta-D-ribofuranosyl-1,3,5-triazin-2(1H)-one

5 AZC

5-AC

5-Aza-cytidine

5-Azacytidine

5-AZC

Azacitidine

azacitidine

AZACITIDINE

Azacytidine

Azacytidine, 5-

Ladakamycin

Mylosar

Onureg

U-18496

Vidaza

 

- New York: Memorial Sloan-Kettering Cancer Center New York

 

Location

United States, New Jersey

United States, New York




Posts Archive